Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.64 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429149 | 0.94 | AGTR1 (0.57) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL3873571 | 0.94 | AGTR2 (0.56) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL10108979 | 0.92 | AGTR1 (0.66) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL9594207 | 0.91 | AGTR1 (0.54) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL28915096 | 0.91 | AGTR2 (0.54) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL8112903 | 0.89 | AGTR2 (0.52) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL14573953 | 0.89 | AGTR2 (0.49) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL8203606 | 0.88 | AGTR1 (0.69) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL15478917 | 0.87 | AGTR1 (0.68) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL5270410 | 0.87 | AGTR1 (0.68) | AGTR1AGTR2ABCB11EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247595-A1 | Process for the preparation of tetrazolyl compounds | MEDICHEM, S.A. (ES) | 2009-10-01 | — | — | US | claimed |
| EP-1896455-A2 | PROCESS FOR THE PREPARATION OF TETRAZOLYL COMPOUNDS | Medichem, S.A. (ES) | 2008-03-12 | — | — | EP | claimed |
| WO-2007074399-A2 | PROCESS FOR THE PREPARATION OF TETRAZOLYL COMPOUNDS | MEDICHEM, S.A. (US) | 2007-07-05 | — | — | WO | claimed |
| US-7153972-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2006-12-26 | — | — | US | claimed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | claimed |
| US-6844443-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2005-01-18 | — | — | US | claimed |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-03-04 | — | — | US | claimed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | claimed |
| CN-112745302-A | Benzimidazole compound and medical application thereof | 上海中医药大学附属龙华医院 | 2021-05-04 | — | — | CN | disclosed |
| US-20180155326-A1 | METHOD FOR PREPARING TRITYL CANDESARTAN | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2018-06-07 | — | — | US | disclosed |
| EP-2250168-B1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | disclosed |
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2244575-B1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-0459136-B1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| US-5401764-A | Hypotensive agents or cardiovascular disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5328919-A | Antagonist of Angiotensin for cardiovascular disorders and hypotensive | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| US-5196444-A | Angiotensin/II/ antagonists; hypotensive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | AGTR1 1906/4885AGTR2 2490/4885ABCB11 1224/4885 |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, H1-4 | AGTR1 2302/4885AGTR2 2919/4885ABCB11 1312/4885 |
| US-20090247595-A1 | Process for the preparation of tetrazolyl compounds | TLL1, TLL2, TPP1 | AGTR1 4/4885AGTR2 6/4885ABCB11 3494/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | AGTR1 2191/4885AGTR2 2836/4885ABCB11 1237/4885 |
| US-20180155326-A1 | METHOD FOR PREPARING TRITYL CANDESARTAN | ACE, REN, AGT | AGTR1 4/4885AGTR2 6/4885ABCB11 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.